ATE170564T1 - Retrovirale vektoren zur tumorbehandlung und sie enthaltende zelllinien - Google Patents

Retrovirale vektoren zur tumorbehandlung und sie enthaltende zelllinien

Info

Publication number
ATE170564T1
ATE170564T1 AT94902825T AT94902825T ATE170564T1 AT E170564 T1 ATE170564 T1 AT E170564T1 AT 94902825 T AT94902825 T AT 94902825T AT 94902825 T AT94902825 T AT 94902825T AT E170564 T1 ATE170564 T1 AT E170564T1
Authority
AT
Austria
Prior art keywords
pct
retroviral vectors
cells
cell lines
tumor treatment
Prior art date
Application number
AT94902825T
Other languages
English (en)
Inventor
David Klatzmann
Manuel Caruso
Original Assignee
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Curie filed Critical Univ Paris Curie
Application granted granted Critical
Publication of ATE170564T1 publication Critical patent/ATE170564T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94902825T 1992-12-16 1993-12-16 Retrovirale vektoren zur tumorbehandlung und sie enthaltende zelllinien ATE170564T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9215195A FR2699191B1 (fr) 1992-12-16 1992-12-16 Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.

Publications (1)

Publication Number Publication Date
ATE170564T1 true ATE170564T1 (de) 1998-09-15

Family

ID=9436686

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94902825T ATE170564T1 (de) 1992-12-16 1993-12-16 Retrovirale vektoren zur tumorbehandlung und sie enthaltende zelllinien

Country Status (10)

Country Link
US (1) US5843432A (de)
EP (1) EP0674716B1 (de)
JP (1) JPH08506722A (de)
AT (1) ATE170564T1 (de)
CA (1) CA2150536A1 (de)
DE (1) DE69320831T2 (de)
DK (1) DK0674716T3 (de)
ES (1) ES2123753T3 (de)
FR (1) FR2699191B1 (de)
WO (1) WO1994013824A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
EP0758387B1 (de) * 1994-05-02 2001-12-19 University of Washington Thymidin-kinase-mutanten
FR2723962B1 (fr) * 1994-08-25 1996-10-31 Univ Paris Curie Hsv1-tk modifiee fonctionnelle
JPH09511405A (ja) * 1994-09-08 1997-11-18 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング レトロウイルスベクターハイブリッド及びその遺伝子転移のための使用
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
CA2218808A1 (en) * 1995-05-10 1996-11-14 Introgene B.V. Improved retroviral vectors, especially suitable for gene therapy
FR2736931B1 (fr) 1995-07-17 1997-09-19 Univ Paris Curie Sequences regulatrices issues du gene cd4 et a expression specifique dans les lymphocytes t matures
US7169764B1 (en) 1995-10-05 2007-01-30 Arch Development Corporation Promoter for smooth muscle cell expression
US6090618A (en) 1996-10-07 2000-07-18 Arch Development Corporation DNA constructs and viral vectors comprising a smooth muscle promoter
FR2746815A1 (fr) * 1996-03-26 1997-10-03 Pasteur Institut Sequences en amont du gene sm 22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires
EP0803573A1 (de) * 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronische Expressionskonstrukt mit Cytokinen für multivalente Impstoffe
FR2751345B1 (fr) 1996-07-16 1998-09-18 Univ Paris Curie Lignees d'encapsidation hautement productrices
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US6087164A (en) 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
AU3499801A (en) * 2000-02-11 2001-08-20 Schepens Eye Res Inst Isolation and transplantation of retinal stem cells
EP1201750A1 (de) * 2000-10-26 2002-05-02 Genopoietic Synthetische Viren und ihre Verwendungen
FR2820146B1 (fr) * 2001-01-29 2003-06-27 Centre Nat Rech Scient Procede d'obtention de cellules d'encapsidation fortement productrices de retrovirus par elimination, au sein de la culture, des cellules permissives a l'infection par le retro virus produit
JP6468843B2 (ja) 2012-02-17 2019-02-13 ザ スキーペンズ アイ リサーチ インスティチュート ヒト網膜前駆細胞の表現型プロファイル
US20220202885A1 (en) * 2019-06-27 2022-06-30 Bionoxx Inc. Oncolytic virus with improved safety and anticancer effects

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells

Also Published As

Publication number Publication date
EP0674716B1 (de) 1998-09-02
JPH08506722A (ja) 1996-07-23
DK0674716T3 (da) 1999-06-07
ES2123753T3 (es) 1999-01-16
WO1994013824A1 (fr) 1994-06-23
DE69320831D1 (de) 1998-10-08
FR2699191B1 (fr) 1995-02-10
FR2699191A1 (fr) 1994-06-17
US5843432A (en) 1998-12-01
CA2150536A1 (fr) 1994-06-23
DE69320831T2 (de) 1999-04-01
EP0674716A1 (de) 1995-10-04

Similar Documents

Publication Publication Date Title
DE69320831D1 (de) Retrovirale vektoren zur tumorbehandlung und sie enthaltende zelllinien
Subramanyam et al. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness
Gutwein et al. Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells
Hattori et al. Involvement of tryptase-related cellular protease (s) in human immunodeficiency virus type 1 infection
Mathes et al. Abrogation of lymphocyte blastogenesis by a feline leukaemia virus protein
Byrd et al. Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44
ATE175997T1 (de) Behandlung von zellpopulationen
DK0915910T3 (da) Exendin-analoger, fremgangsmåder til fremstilling deraf samt lægemidlter der indeholder disse
Tung et al. Direct activation of protein phosphatase‐2A0 by HIV‐1 encoded protein complex NCp7: vpr
FI942228A0 (fi) Bacillus licheniformiksen x-amylaasipromoottorin variantista johdettu Bacillus-promoottori
ATE275343T1 (de) Verarbeitung von pflantzlichem material mit xylanase
ATE113262T1 (de) Bioreaktor.
DE69830513D1 (de) HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN
GB2331522A (en) Lentiviral vectors
BR9507618A (pt) Frações polipeptidicas solúveis da proteína lag-3 processo de produção composição terapêutica anticorpos anti-idiotipo
DE69625183D1 (en) Heterocyclocarbonyl-aminosäure-hydroxyethylamino-sulfonamid inhibitoren retroviraler proteasen
SE8902532L (sv) Bestaemning av plasmaproteiner
GR3022832T3 (en) Assay technique
Kido et al. Tryptase TL2 in the membrane of human T4+ lymphocytes is a novel binding protein of the V3 domain of HIV-1 envelope glycoprotein gp120
ATE244310T1 (de) Retrovirale vektorhybride und deren verwendung zum gentransfer
ATE104551T1 (de) S-adenosylmethionin zur behandlung von pankreatitis und der immunabstossung des pankreastransplantates.
ATE354374T1 (de) Zusammensetzungen und methoden zur katalysierten hydrolyse von hiv gp120
ATE179164T1 (de) Hiv-proteaseinhibitoren
ATE165005T1 (de) Dextrinsulfate als anti hiv-1 wirkstoffe und diese enthaltende zubereitungen
Yeung et al. Inhibition of HIV-1 gp120-induced apoptosis in neuroblastoma SK-N-SH cells by an antisense oligodeoxynucleotide against p53

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee